

## PRESSEMITTEILUNG

---

### Agreement on development contract: ProBioGen and Affimed continue their collaboration.

Berlin, Heidelberg, 14th February 2006 - ProBioGen, the international cell specialists from Berlin, and Heidelberg based Affimed Therapeutics AG, specializing in the development of recombinant antibodies for the treatment of cancer, announce the execution of a development collaboration. Within the frame of this contract, ProBioGen will develop a high-producing cell-line as well as a production process and procedure with GMP-manufacturing for clinical material for a TandAB, a bi-specific, tetravalent recombinant antibody, from Affimed.

Meanwhile, both companies are discussing extending their collaboration to other products. The co-operation between ProBioGen and Affimed reached a new level of intensity with this contract. "We are very happy to use our expression technology for a key product for Affimed", said Michael Schlenk, CEO of ProBioGen. "It has already become obvious during our negotiations that the cultures of our enterprises fit very well together."

"ProBioGen's high competence and professional project management really convinced us. The collaboration has been very constructive from the beginning based on a highly efficient exchange of information and is already showing first promising results. Thus, we are looking forward to extending our collaboration expecting significant benefits for the development of our products," said Dr. Rolf H. Günther, CEO of Affimed.

## About ProBioGen AG

ProBioGen AG is a specialist for cell line design, viral vectors, and the manufacture of glycoproteins for the biopharmaceutical industry. Its range of products and services includes the design of novel cell lines from primary tissue, the development of highly productive mammalian cell lines, as well as the manufacture of glycoproteins for clinical studies. ProBioGen possesses the manufacturing authorization for pharmaceutically usable active substances for testing in clinical studies and meets the quality standards recommended by the EU (EMA) and the FDA. A certified cGMP multipurpose facility is available for the contract production of biopharmaceutical active substances. The company combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen accompanies its clients through all stages, from the development of product candidates to the clinical testing phase.

## About AFFIMED Therapeutics AG

Affimed is a private Heidelberg, Germany-based biopharmaceutical company specializing in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May 2000 by Professor Melvyn Little as a spin-off of his group "Recombinant Antibodies" at the German Cancer Research Centre in Heidelberg. By utilizing its broad portfolio of proprietary, in-house technology platforms together with crucial enabling freedom-to-operate licenses the company has been able to establish a pre-clinical product pipeline of promising novel product candidates mainly for indications in oncology and autoimmune diseases. Two cancer products are in advanced pre-clinical development. Further products are being developed in a partnership with Syngenta Biopharma.

### ProBioGen Contact

*Michael Schlenk*  
*Goethestraße 54*  
*13068 Berlin*  
*Tel.: +49 (30) 924-006-0*  
*Fax: +49 (30) 924-006-19*  
*e-mail: [michael.schlenk@probiogen.de](mailto:michael.schlenk@probiogen.de)*

### Affimed Contact

*Dr. Florian Fischer*  
*Im Neuenheimer Feld 582*  
*D-69120 Heidelberg*  
*+49 (0) 6221- 65307-0*  
*+49 (0) 6221- 65307-77*  
*e-mail: [f.fischer@affimed.com](mailto:f.fischer@affimed.com)*